To comparatively define the roles of HIF1α and HIF2α in AML, we interfered with their expression in cell lines representative of favorable (Kasumi1 and NB4 cells) or high‐risk (Molm13 and THP1 cells) patients' categories, including cell lines conventionally used for differentiation studies (HL60 and NB4 cells). This evidence concerns the gene HIF1A and acute myeloid leukemia.